GlobeNewswire by notified

Beter Bed Holding continues sales growth with +15.6% in first half year of 2022 and forms manufacturing joint venture in Poland

Share

Beter Bed Holding N.V. (BBH) – the Netherlands’ leading sleep specialist in retail, wholesale and B2B – today announced its results for the second quarter and first half year ended 30 June 2022.

Highlights first half 2022

  • Sales growth of +15.6% to € 112.4 million (H1 2021: € 97.2 million) with gross profit increase of +12.6% to € 61.2 million.
  • Continued performance with Compound Annual Growth Rate over H1 2019 to H1 2022 (CAGR) of +9.5% in sales and +9.7% in order intake.
  • EBITDA and EBIT of respectively € 13.7 million and € 3.7 million, in line with same period last year.
  • Online sales CAGR of +38.7% since 2019, leading to online channel share of 19.7%.
  • Strong performance of New Business with +13.5% sales growth compared to H1 2021.
  • Order book at € 19.4 million (-24.1% compared to 30 June 2021).
  • DBC signs agreement with the French Adova Group to get the exclusive right to sell the Simmons brand (Generation collection) in the Netherlands and the Flemish part of Belgium.
  • Binding memorandum of understanding signed with long-standing suppliers to acquire 33.3% interest in Polish bedding and mattresses factory.
  • Newly developed supply chain network strategy to support the 2025 medium-term objectives.

JohnKruijssen,CEOofBBH,comments:
“BBH again shows a half year of solid growth. Although the second quarter has been somewhat softer, mainly due to the strong comparison base, we have made good progress during the period and further grown our gross profit. We have proven that our proposition fits the needs of the customers and people increasingly recognise the importance of sleep for their health. With our strong execution capabilities, strong store network and continuously growing online presence, we remain confident that we can weather the current challenges driven by the war in Ukraine, inflation, recession, rising commodity prices and difficult labour market. We continue to adjust and strengthen our proposition and are making strong strategic progress. To further secure and streamline the supply of high-quality products for our customers, we aim to vertically integrate our value chain and I am happy to announce that we have signed a binding memorandum of understanding to form a joint venture with a long-standing strategic supplier. This partnershipcreates innovative power, purchasing advantage of raw materials, and more influence on margin among other things. DBC also made significant progress in the last quarters with existing and new partnerships and continued to showsales growth. We expect that the retail sector will be impacted by the low consumer spending due to the uncertainties in the market, however we are confident BBH is resilient in character and ideas and is on track to realise the 2025 targets.”

For the complete version of the press release please click on the link under attachment(s).

Press photos can be downloaded here.



Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date25.4.2024 07:30:00 CEST | Press release

Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its Full Year 2023 Financial and Operating Results. “In 2023, we made substantial progress against our objectives and laid the foundation to bring our ARC-EX System to the US market later this year,” said Dave Marver, CEO of ONWARD Medical. “We are off to a strong start again in 2024, raising EUR 20M in equity capital and submitting our De Novo application to the FDA for the ARC-EX System.” Full Year 2

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance25.4.2024 07:30:00 CEST | Press release

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performanceR&D expenses grew 11.8%, reflecting strategic shift of resources into developmentSG&A expenses grew 2.9%, less than sales growthBusiness EPS(1) of €1.78, down 17.6% reported and 7.4% at CERIFRS EPS of €0.91, down 43.1% reported R&D transformation advanced further Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in JapanPositive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare diseaseReaffirming increasing pipeline news flow over 2024-2

Huhtamäki Oyj’s Interim Report January 1–March 31, 2024: Improved operational profitability25.4.2024 07:30:00 CEST | Press release

HUHTAMÄKI OYJ INTERIM REPORT 25.4.2024 AT 8:30 EEST Q1 2024 in brief Net sales decreased 4% to EUR 1,004 million (EUR 1,047 million)Comparable net sales growth was -2% at Group levelReported EBIT was EUR 78 million (EUR 87 million); adjusted EBIT was EUR 99 million (EUR 92 million)Reported EPS was EUR 0.35 (EUR 0.47); adjusted EPS was EUR 0.55 (EUR 0.51)The impact of currency movements was EUR -17 million on the Group's net sales and EUR -2 million on EBIT Key figures EUR million Q1 2024 Q1 2023 Change 2023 Net sales 1,003.9 1,047.1 -4% 4,168.9 Comparable net sales growth -2% 2% -2% Adjusted EBITDA1 149.0 140.5 6% 590.1 Margin1 14.8% 13.4% 14.2% EBITDA 137.7 138.1 -0% 621.2 Adjusted EBIT2 98.8 92.1 7% 392.6 Margin2 9.8% 8.8% 9.4% EBIT 77.6 87.4 -11% 380.9 Adjusted EPS, EUR3 0.55 0.51 7% 2.32 EPS, EUR 0.35 0.47 -27% 1.97 Adjusted ROI2 11.5% 10.7% 11.2% Adjusted ROE3 13.3% 13.7% 13.2% ROI 10.7% 11.0% 10.9% ROE 11.0% 14.3% 11.8% Capital expenditure 36.6 65.2 -44% 318.7 Free Cash Flow 38.2

TRAINERS’ HOUSE GROUP INTERIM REPORT 1 JANUARY – 31 MARCH 202425.4.2024 07:30:00 CEST | Press release

TRAINERS' HOUSE GROUP, STOCK EXCHANGE RELEASE, 25 APRIL 2024 at 8:30 January-March 2024 in brief net sales EUR 2.3 million (EUR 2.8 million), change of -18.3 % compared to the corresponding period of the previous yearoperating result EUR 0.2 million (EUR 0.4 million), 7.3 % of net sales (14.5 %)cash flow from operations EUR 0.2 million (EUR 0.3 million)earnings per share EUR 0.08 (EUR 0.19) Key figures at the end of first quarter of 2024 cash and cash equivalents EUR 1.3 million (EUR 2.5 million)interest-bearing liabilities of EUR 0.8 million (EUR 0.4 million) and interest-bearing net debt of EUR -0.5 million (EUR -2.1 million).equity ratio 64.3 % (59.5 %) OUTLOOK FOR 2024 The company estimates the operating profit for 2024 to be negative. CEO ARTO HEIMONEN In the review period, acquiring new orders was challenging. The demand for services connected to overall well-being, mental growth and creating of meanings is growing. The sales of the company's personal training products strengthen

Flow Traders Q1 2024 Trading Update25.4.2024 07:30:00 CEST | Press release

Flow Traders Q1 2024 Trading Update Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited Q1 2024 trading update. Highlights Flow Traders recorded Net Trading Income of €127.1m and Total Income of €129.6m in Q124, compared to €72.7m and €74.3m, respectively, in Q423, and €110.5m for both in Q123. Flow Traders’ Value Traded increased 7% in Q124 when compared to last quarter and was flat when compared to the same period last year.Total Operating Expenses were €68.5m in Q124, compared to €62.5m in Q423 and €70.3m in Q123, with Fixed Operating Expenses of €43.6m, compared to €40.4m in Q423 and €43.9m in Q123.EBITDA was €61.1m in Q124, generating an EBITDA margin of 47%, compared to €11.8m and 16% in Q423 and €40.2m and 36% in Q123. Net Profit was €45.9m in Q124, yielding a basic EPS of €1.06, compared to €6.4m of Net Profit and €0.15 of basic EPS in Q423 and €27.7m and €0.64 in Q123. Trading capital stood at €609m at the end of Q124 and generated a 52% ret

HiddenA line styled icon from Orion Icon Library.Eye